In this pooled analysis of the Measure Up 1 and Measure Up 2 studies, adults and adolescents with moderate-to-severe atopic dermatitis who received once-daily upadacitinib (15 or 30 mg) treatment experienced early improvements in symptoms and quality of life. |
Within 1–2 weeks of initiating upadacitinib therapy, improvements were observed in patient-reported outcomes measuring itch, pain, other skin symptoms, sleep, daily activities, emotional state, quality of life, impression of disease severity, impression of treatment efficacy, and treatment satisfaction. |
Improvements in patient-reported outcomes increased steadily after weeks 1–2 and were maintained through week 52 of upadacitinib treatment. |
1 Introduction
2 Methods
2.1 Study Design
2.2 Patients
2.3 Assessments
2.4 Statistical Analysis
3 Results
3.1 Patients
Characteristic | UPA 15 mg (N = 557) | UPA 30 mg (N = 567) | PBO (N = 485) |
---|---|---|---|
Sex, n (%) | |||
Female Male | 245 (44.0) 312 (56.0) | 250 (44.1) 317 (55.9) | 232 (47.8) 253 (52.2) |
Age, years, mean (SD) | 33.7 (15.7) | 33.9 (15.9) | 33.8 (15.2) |
Age group, years, n (%) | |||
< 18 ≥ 18 | 75 (13.5) 482 (86.5) | 77 (13.6) 490 (86.4) | 69 (14.2) 416 (85.8) |
Race, n (%) | |||
White Asian Black or African American American Indian/Alaska Native Native Hawaiian/Other Pacific Islander Multiple | 366 (65.7) 128 (23.0) 43 (7.7) 5 (0.9) 3 (0.5) 12 (2.2) | 389 (68.6) 133 (23.5) 25 (4.4) 2 (0.4) 1 (0.2) 17 (3.0) | 328 (67.6) 105 (21.6) 33 (6.8) 7 (1.4) 2 (0.4) 10 (2.1) |
Hispanic or Latino, n (%) | 58 (10.4) | 63 (11.1) | 58 (12.0) |
BMI, kg/m2, mean (SD) | 25.8 (5.9) | 25.8 (5.8) | 26.6 (6.0) |
vIGA-AD score, n (%) | |||
3 (moderate) 4 (severe) | 280 (50.3) 277 (49.7) | 280 (49.4) 287 (50.6) | 252 (52.0) 233 (48.0) |
EASI, mean (SD) | 29.6 (12.3) | 29.3 (11.7) | 28.6 (12.4) |
Weekly WP-NRS, mean (SD) | 7.2 (1.6) | 7.3 (1.5) | 7.3 (1.6) |
SCORAD, mean (SD) | 67.4 (12.6) | 67.0 (12.7) | 66.8 (12.6) |
DLQI, mean (SD) | 16.6 (7.0) | 16.5 (6.9) | 16.8 (7.0) |
POEM, mean (SD)b | 21.2 (4.9) | 21.6 (5.0) | 21.6 (5.3) |
ADerm-SS Skin Pain, mean (SD) | 6.3 (2.2) | 6.4 (2.2) | 6.4 (2.3) |
ADerm-SS TSS-7, mean (SD) | 46.3 (13.6) | 46.3 (13.6) | 46.6 (13.8) |
ADerm-IS Sleep, mean (SD) | 18.2 (7.4) | 18.5 (7.6) | 19.0 (7.6) |
ADerm-IS Daily Activities, mean (SD) | 23.1 (10.5) | 22.8 (10.6) | 23.2 (10.6) |
ADerm-IS Emotional State, mean (SD) | 20.4 (7.9) | 20.1 (8.3) | 20.2 (8.0) |
HADS, mean (SD) | 12.5 (7.3) | 13.0 (7.7) | 12.5 (7.7) |